Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Eye2Gene explores the use of AI to determine which genetic condition is causing a patient’s inherited retinal disease, by examining eye scans.

retina

Eye2Gene is led by Dr Nikolas Pontikos at UCL, Professor Susan Downes at Oxford and Savita Madhusudhan at Liverpool.

The Department of Health and Social Care awarded £1.3M to phase 2 of the Eye2Gene project as part of its Artificial Intelligence in Health & Care Award. This Award makes £140 million available over four years to accelerate the testing and evaluation of artificial intelligence technologies which meet the aims set out in the NHS Long Term Plan.

The Award aims to increase the impact of AI-driven technologies to help solve clinical and operational challenges across the NHS and care settings. It will speed up the most promising technologies through the regulatory process by building an evidence base to demonstrate the effectiveness and safety of AI-driven technologies in health and social care.

With more than 300 possible genetic causes of inherited retinal disease, requiring differing management or treatment options, swift diagnosis is crucial. The Eye2Gene technology has been developed at UCL and Moorfields, and will be validated at Oxford University Hospital and the other sites.

The clinical safety officer, Dr Mital Shah from Oxford, will be responsible for overseeing the safety and efficacy of Eye2Gene in a retrospective observational evaluation on clinical scans from patients with a confirmed genetic diagnosis that will be collected from the participating sites.

Phase 2 of the project starts on 1 January 2022 and will last for three years, during which Eye2Gene will be developed into a software as a medical device to be used for decision support.

Similar stories

Evaluating risk to people with epilepsy during the COVID-19 pandemic - study wins international prize

In May 2020 our researchers initiated a global project to investigate how COVID-19 has affected people with epilepsy, their carers and health care workers.

New European initiative to accelerate the discovery and validation of biomarkers for neurodegenerative diseases

Members of the European Platform for Neurodegenerative Diseases (EPND) will establish a collaborative platform for efficient sample and data sharing, linking existing European research infrastructures to accelerate the discovery of biomarkers, new diagnostics and treatments for the benefit of people with neurodegenerative diseases such as Alzheimer's and Parkinson's.

Major research network to investigate body clock and stroke

The University of Oxford is part of a new international research network to investigate the interactions between the biology of the body's internal clock and the disordered physiological processes associated with stroke.

COVID-19 infection has greater risk than vaccines of causing very rare neurological events

Research reveals risks of developing neurological complications following a positive COVID-19 PCR test, or a first dose of either the Oxford-AstraZeneca or Pfizer-BioNTech COVID-19 vaccinations.

Mapping uncharted networks in the progression of Parkinson’s

A major new $9 million project funded by the Aligning Science Across Parkinson’s (ASAP) initiative will map the original circuits vulnerable to Parkinson’s on an unprecedented scale. The project is a collaboration between core investigators Stephanie Cragg, Richard Wade-Martins, and Peter Magill at Oxford, Mark Howe at Boston University and Dinos Meletis at the Karolinska Institutet, as well as collaborators Yulong Li at Peking University and Michael Lin at Stanford University.